Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kathleen Dorritie
- Target Recruit Count
- 34
- Registration Number
- NCT06050512
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-02-10
- Target Recruit Count
- 100
- Registration Number
- NCT05722405
- Locations
- 🇨🇳
Yang Xu, Hangzhou, Zhejiang, China
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Rajshekhar Chakraborty, MD
- Target Recruit Count
- 53
- Registration Number
- NCT05451771
- Locations
- 🇺🇸
New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Takeda
- Registration Number
- NCT05183139
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04998786
- Locations
- 🇫🇷
CHR, Annecy, France
🇫🇷CHU Henri Mondor, Paris, France
🇫🇷CHRU, Rennes, France
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Michael M. Pham
- Target Recruit Count
- 3
- Registration Number
- NCT04837131
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14
- Registration Number
- NCT04272775
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 211
- Registration Number
- NCT04217967
- Locations
- 🇨🇳
PekingUMCH, Beijing, Beijing, China
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Andrew Yee, MD
- Target Recruit Count
- 2
- Registration Number
- NCT04119336
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Mass General/North Shore Cancer Center, Danvers, Massachusetts, United States
Ixazomib + Pomalidomide + Dexamethasone In MM
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 61
- Registration Number
- NCT04094961
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.